Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130